Effect of Paced HR on Central BP

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

22 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-09-21

Study Completion Date

2024-09-10

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Central (aortic) blood pressure predicts heart, brain and kidney complications more reliably than the usual peripherally measured blood pressure. Heart rate has a strong and sometimes counter-intuitive influence on central blood pressure. Pacemakers implanted due to sick sinus syndrome (SSS) are typically programmed anywhere between 55-75 beats per minute (bpm), yet it is unclear which rate gives hypertensive pacemaker recipients the most favourable central hemodynamics.

This single-center, randomized, single-blind, two-period cross-over trial will enrol 20 adults (18-80 years) who already carry a dual-chamber pacemaker for SSS, are in sinus rhythm, and have medication-controlled arterial hypertension. Each participant will complete two eight-week pacing periods in random order:

* "Slow" period - pacemaker lower-rate set to 55 bpm.
* "Fast" period - pacemaker lower-rate set to 75 bpm.

A two-week wash-out at the device's usual settings separates the periods. At baseline and after each intervention the team will perform non-invasive pulse-wave analysis (SphygmoCor XCEL) to obtain central systolic blood pressure (primary endpoint) and arterial stiffness indices such as augmentation index and pulse-wave velocity (secondary endpoints). Pacemaker function, symptoms and safety events are reviewed at every visit; settings can be adjusted by ±5 bpm if troublesome symptoms occur.

The study will provide the first long-term evidence on how fixed pacing rates modulate central blood pressure in real-world SSS patients with hypertension, potentially guiding clinicians toward the optimal programming strategy.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Long-term Atrial Pacing and Central Blood Pressure

NCT04309175

Blood Pressure

UNKNOWN NA

Impact of Pacing Site and AV Delay on Blood Pressure in Hypertensive Patients

NCT02382484

Hypertension

COMPLETED NA

RV Septal Versus Minimized RV Pacing in Sick Sinus Syndrome

NCT01477138

Sick Sinus Syndrome

UNKNOWN

Transpulmonary Thermodilution Measurements in Patients With Heart Diseases

NCT02035007

Heart Diseases

COMPLETED PHASE4

Effects Rapid Atrial Pacing Has on the Electrocardiogram (ECG) in Patients With Dual Chamber Pacemakers

NCT00883610

Prolonged QT Interval

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Scientific background and rationale Arterial hypertension remains the leading modifiable contributor to cardiovascular morbidity. Unlike brachial pressure, central (aortic) systolic pressure directly loads the left ventricle and cerebral and renal arteries. Epidemiological data show that central pressure is more closely associated with left-ventricular hypertrophy, carotid atherosclerosis and clinical events than peripheral pressure. Heart rate (HR) alters the timing of pulse-wave reflections and can therefore change central pressure in ways that are not apparent from arm-cuff readings.

Pharmacological HR reduction (e.g., ivabradine) has been shown to raise central systolic pressure even while lowering brachial pressure, whereas β-blockers exert mixed HR-dependent and HR-independent effects. In acute pacing studies, lowering HR from 80 bpm to \~60 bpm reduced brachial pressure but left central pressure unchanged; allowing HR to fall to \~50 bpm sometimes lowered or sometimes raised central pressure depending on study design. No prospective trial has tested whether a chronically lower versus higher pacemaker rate produces a durable difference in central hemodynamics in patients who require pacing for SSS.

Objectives Primary: Compare clinic-measured central systolic blood pressure after 8 weeks of pacing at 55 bpm versus 75 bpm.

Secondary: Compare additional central hemodynamic indices (augmentation index, pulse pressure amplification, carotid-femoral pulse-wave velocity), brachial blood pressure, and frequency of pacing-related symptoms and atrial arrhythmias between the two settings.

Study design

* Single-center, randomized, single-blind, cross-over.
* Two 8-week intervention periods separated by a 2-week wash-out.
* Allocation ratio 1:1, block randomization, concealed in sequentially numbered opaque envelopes prepared by an independent statistician.

Visit schedule

T-2 (pre-screen) → T-1 (final screen + baseline PWA) → T0 (randomization) → T1 (programming of first rate) → 8 weeks → F1 (end-of-period assessments, device reset) → 2-week wash-out → T2 (second baseline) → program second rate → 8 weeks → F2 (final assessments, device returned to pre-study settings). Total participation ≈20 weeks.

Participants Inclusion

1. Age 18-80 years.
2. Dual-chamber pacemaker implanted ≥3 months for SSS.
3. Sinus rhythm; atrial pacing \>80%, ventricular pacing \<3% since last device check.
4. Medication-treated primary hypertension with clinic BP \< 140/90 mmHg and home BP \< 135/85 mmHg.
5. Able to provide informed consent and comply with procedures. Exclusion (abridged)

* Significant AV block, paced QRS ≥ 130 ms, \>3 antihypertensives, digoxin or class Ic/III/IV antiarrhythmics, frequent atrial tachyarrhythmia (\>3% AMS episodes), coronary intervention on \>1 vessel, LVEF ≤ 40%, CRT or ICD, significant valvular disease, congenital heart disease, BMI ≥ 35 kg/m², diabetes with complications or on insulin, advanced renal, hepatic or pulmonary disease, systemic inflammatory disease, malignancy under recent active therapy, pregnancy or lactation, substance misuse, or inability to complete follow-up.

Interventions Pacemaker lower-rate limit is set to either 55 bpm or 75 bpm using a Merlin™ Patient Care programmer (Abbott/St Jude Medical). All other device parameters remain unchanged unless clinically indicated. If intolerable palpitations, dizziness or dyspnoea occur, HR may be adjusted by ±5 bpm within protocol limits; the participant may continue.

Sample size and statistics The initial 20-patient cohort (2020-2022) showed a within-person SD of 5 mmHg for central systolic BP. Detecting a 3 mmHg difference with 80% power at α = 0.05 in a cross-over design requires 38 completed participants; 20 additional individuals will therefore be recruited (total = 40) to allow for 5% attrition. Analysis will follow an intention-to-treat principle.

Data collection methods

Pulse-wave analysis: SphygmoCor XCEL (AtCor Medical) brachial cuff acquisition with generalized transfer function yields central waveforms. Carotid-femoral pulse-wave velocity is obtained by simultaneous carotid tonometry and femoral cuff recording with surface tape measurement of path length. Standardized seated brachial BP is averaged from triplicate readings. Home BP is logged using a validated oscillometric device. Device diagnostics supply pacing percentages and arrhythmia burden.

Safety, monitoring and ethics All procedures mirror routine pacemaker follow-up except for deliberate lower-rate reprogramming, which falls within the accepted clinical range (55-75 bpm). The prior 20-participant phase recorded two episodes of atrial fibrillation requiring treatment and no serious device malfunctions. Adverse events will be reported to the ethics committee within 15 days. The study complies with the Declaration of Helsinki, EU GDPR and ICH-GCP. Data are pseudonymised; records are stored on secure servers for 10 years, after which they are destroyed. The University of Tartu Human Research Ethics Committee has approved the protocol (initial approval 299/T-22, renewed 2025).

Dissemination Results will be submitted to a peer-reviewed cardiovascular journal, presented at international cardiology conferences.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Sick Sinus Syndrome Hypertension

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

"Slow" arm

Pacemaker base rate set at 55 bpm

Group Type EXPERIMENTAL

Pacemaker and defibrillator

Intervention Type DEVICE

Setting the pacemaker base rate at a pre-defined base rate

"Fast" arm

Pacemaker base rate set at 75 bpm

Group Type EXPERIMENTAL

Pacemaker and defibrillator

Intervention Type DEVICE

Setting the pacemaker base rate at a pre-defined base rate

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Pacemaker and defibrillator

Setting the pacemaker base rate at a pre-defined base rate

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Age 18-80 years.
2. Dual-chamber pacemaker implanted ≥3 months for SSS.
3. Sinus rhythm; atrial pacing \>80%, ventricular pacing \<3% since last device check.
4. Medication-treated primary hypertension with clinic BP \< 140/90 mmHg and home BP \< 135/85 mmHg.
5. Able to provide informed consent and comply with procedures.

Exclusion Criteria

Significant AV block, paced QRS ≥ 130 ms, \>3 antihypertensives, digoxin or class Ic/III/IV antiarrhythmics, frequent atrial tachyarrhythmia (\>3% AMS episodes), coronary intervention on \>1 vessel, LVEF ≤ 40%, CRT or ICD, significant valvular disease, congenital heart disease, BMI ≥ 35 kg/m², diabetes with complications or on insulin, advanced renal, hepatic or pulmonary disease, systemic inflammatory disease, malignancy under recent active therapy, pregnancy or lactation, substance misuse, or inability to complete follow-up.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No